Figure 1.
Enhanced TG in the blood compared with PRP for all coagulant triggers. TG in the whole blood or PRP was triggered in the presence of CaCl2/MgCl2 with vehicle medium or tissue factor (0.1-1.0 pM) (Ai-iii), Rvv-X activator (dilutions, 1e–3 to 1e–7) (Bi-iii), factor Xa (FXa, 0.1-10 nM) (Ci-iii), or 0.1 to 10 nM thrombin (Di-iii). Shown are representative curves of nanomolar calibrated TG for each trigger. Calibrated curves of TG were quantitatively assessed for lagtime (E) and thrombin peak level (F) per trigger and dose. Each condition was performed in parallel with whole blood and corresponding PRP from 3 donors (n = 3) using 2-way analysis of variance (ANOVA); #P < .10; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. Complete data are provided in Datafile 1. TF, tissue factor.

Enhanced TG in the blood compared with PRP for all coagulant triggers. TG in the whole blood or PRP was triggered in the presence of CaCl2/MgCl2 with vehicle medium or tissue factor (0.1-1.0 pM) (Ai-iii), Rvv-X activator (dilutions, 1e–3 to 1e–7) (Bi-iii), factor Xa (FXa, 0.1-10 nM) (Ci-iii), or 0.1 to 10 nM thrombin (Di-iii). Shown are representative curves of nanomolar calibrated TG for each trigger. Calibrated curves of TG were quantitatively assessed for lagtime (E) and thrombin peak level (F) per trigger and dose. Each condition was performed in parallel with whole blood and corresponding PRP from 3 donors (n = 3) using 2-way analysis of variance (ANOVA); #P < .10; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. Complete data are provided in Datafile 1. TF, tissue factor.

Close Modal

or Create an Account

Close Modal
Close Modal